Aureon Laboratories to Collaborate with Pfizer, Inc. to Establish Quantitative Biometrics...

Aureon Laboratories to Collaborate with Pfizer, Inc. to Establish Quantitative Biometrics for Assessing Therapeutic Response of Prostate Cancer Patients Treated with Hormone Therapy

YONKERS, N.Y.--(Business Wire)--Aureon Laboratories, Inc. today announced a new phase in a
research collaboration with Pfizer, Inc. that shall establish
quantitative biometrics for assessing therapeutic response derived
from studies focusing on prostate cancer. The collaboration will
utilize Aureon's integrated systems pathology approach, whereby data
generated from tissue morphometry, multiplexed-protein biomarkers, and
in situ RNA expression are integrated with patient clinical
information and associated with clinical outcome.

The collaboration is an extension of a previous study performed by
Aureon and Pfizer to evaluate prostatectomy samples from patients
treated with neo-adjuvant androgen deprivation therapy (ADT). The
previous project also demonstrated the technical feasibility of
Aureon's platform in quantifying T-cell subtypes in a lymphoid
infiltrate and the cellular distribution of cytokines using intact
formalin-fixed, paraffin-embedded (FFPE) tissue specimens.

Vijay Aggarwal, PhD, CEO and President of Aureon Laboratories
said, "We are very excited about collaborating with Pfizer on the next
phase of this research project. Aureon's ability to integrate and
quantify histological features and cell-type specific molecular
biomarkers in intact paraffin-embedded tissue allows a better
understanding of the biological context in terms of assessing
therapeutic response."

Aureon technology is also being used to develop Prostate Px+, a
prognostic, biopsy-based test which can assist men who are newly
diagnosed with prostate cancer and need more accurate information to
guide medical management of the disease. Prostate Px+ will be released
in 2008.

About Aureon Laboratories

Aureon Laboratories' mission is to enable personalized patient
care through predictive pathology. Aureon has developed a high
throughput Systems Pathology technology platform to predict individual
clinical outcomes through the interrogation of tissue. The platform
generates and analyzes an integrated, digital view of clinical
findings, tissue micro-anatomy and tissue molecular pathology to
determine which combination of features predicts specified individual
clinical outcomes. Allied with major cancer centers, Aureon operates a
CLIA-certified and CAP-accredited laboratory that provides predictive
pathology services to the practicing physician. For more information
about Aureon, go to www.aureon.com or call 1-888-SYS-PATH.

NOTE: Prostate Px and Px SCORE are registered trademarks of Aureon
Laboratories, Inc.

Aureon Laboratories, Inc.
Jason Alter, Ph.D., 914-377-4036
Fax: 914-377-4001
Jason.Alter@Aureon.com

Copyright Business Wire 2008